Review



human pdac cell lines  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    ATCC human pdac cell lines
    Human Pdac Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1150 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdac+tissue+array/CFPAC-1/ppr0485706-59-3-34
    Average 97 stars, based on 1150 article reviews
    human pdac cell lines - by Bioz Stars, 2026-10
    97/100 stars

    Images

    Related Articles

    Saline:

    Article Title: Combination of antibody-pyrrolobenzodiazepine derivative conjugate and PARP inhibitor
    Article Snippet: .. The human pancreatic cancer cell line CFPAC-1 purchased from ATCC (American Type Culture Collection) was suspended in physiological saline, and 5.0×106 cells were subcutaneously transplanted to the right flank of each female nude mouse, and the mice were randomly grouped 10 days after the transplantation (Day 0). ..

    Transplantation Assay:

    Article Title: Combination of antibody-pyrrolobenzodiazepine derivative conjugate and PARP inhibitor
    Article Snippet: .. The human pancreatic cancer cell line CFPAC-1 purchased from ATCC (American Type Culture Collection) was suspended in physiological saline, and 5.0×106 cells were subcutaneously transplanted to the right flank of each female nude mouse, and the mice were randomly grouped 10 days after the transplantation (Day 0). ..

    Cell Culture:

    Article Title: Evaluating mesothelin as an immunotherapeutic target for endogenous T cells
    Article Snippet: A panel of human cancer cell lines, including pancreatic cancer (CFPAC-1, CAPAN-1), cervical carcinoma (MS751), colon adenocarcinoma (SK-CO-1), breast cancer (Hs578T, HCC1806), uterine adenocarcinoma (KLE), ovarian cancer (OVCAR3), prostate cancer (LNCaP), and mesothelioma (NCI-H2052, NCI-H2452, NCI-H28) were purchased from the American Type Culture Collection (ATCC, Manassas, VA). .. CFPAC-1 and CAPAN-1 cells were cultured in IMDM (Gibco, Waltham, MA); MS751 and SK-CO-1 in EMEM (ATCC); Hs578T and KLE in DMEM (HyClone Laboratories), with KLE additionally supplemented with Ham’s F-12 (Gibco); and OVCAR3, HCC1806, LNCaP, NCI-H2052, NCI-H2452, and NCI-H28 in RPMI-1640. .. All media were supplemented with 10% fetal bovine serum (FBS) (Gibco).

    Protease Inhibitor:

    Article Title: Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies GAPDH Proteintech Cat# 60004-1-Ig; RRID:AB_2107436 PLOD2 Abcam Cat# ab313765 Cytokeratin 19 Aifang Cat# AFRM0054 CD31 Abcam Cat# ab281583; RRID:AB_3096925 Fibronectin Proteintech Cat# 66042-1-Ig; RRID:AB_11182385 S100A2 Proteintech Cat# 15454-1-AP; RRID:AB_3669209 GATA6 Proteintech Cat# 55435-1-AP; RRID:AB_11182815 Paxillin Proteintech Cat# 10029-1-Ig; RRID:AB_513929 Integrin β1 Aifang Cat# AFRM0070 alpha smooth muscle Abcam Cat# ab7817; RRID:AB_262054 FAP Proteintech Cat# 11779-1-AP; RRID:AB_3669133 DUSP6 Proteintech Cat# 26071-1-AP; RRID:AB_3669521 ANGPTL4 Proteintech Cat# 18374-1-AP; RRID:AB_2878539 NDRG1 Proteintech Cat# 26902-1-AP; RRID:AB_2880676 CD45 Abcam Cat# ab281586; RRID:AB_3697165 MCTP2 Proteintech Cat# 17578-1-AP; RRID:AB_2143118 CD3 Abcam Cat# ab16669; RRID:AB_443425 CD68 Abcam Cat# ab283654; RRID:AB_2922954 SYN Proteintech Cat# 17785-1-AP; RRID:AB_2271365 IGF1R Proteintech Cat# 20254-1-AP; RRID:AB_10667455 PPP2R2C Proteintech Cat# 12747-1-AP; RRID:AB_2170099 hCD45 BioLegend Cat# 304008; RRID:AB_314396 mCD45 BioLegend Cat# 103112; RRID:AB_312977 HLA-G Proteintech Cat# 66447-1-Ig anti-Myc-Tag Cell Signaling Technology Cat# 2278; RRID: AB_490778 anti-FLAG Cell Signaling Technology Cat# 14793; RRID: AB_2572291 anti-HA Abcam Cat #ab9110, RRID: AB_307019 Biological samples Human pancreatic cancer tissues This study N/A Patient-derived xenografts This study N/A Chemicals, peptides, and recombinant proteins PROTAC-G3 This study N/A Activin A MedChemExpress Cat# HY-P70311 MG-132 MedChemExpress Cat# HY-13259 Latrunculin A Abcam Cat# ab144290 KP-457 MedChemExpress Cat# HY-110397 Cycloheximide MedChemExpress Cat# HY-12320 (S)-ACE-OH MedChemExpress Cat# HY169325 OVA Peptide MedChemExpress Cat# HY-P1489 Recombinant Streptococcus pyogenes CRISPR-Cas9 Protein (His Tag) SinoBiological Cat: 40572-A08B (Continued on next page) ll OPEN ACCESSArticle Cancer Cell 44, 1–16.e1–e11, August 10, 2026 e1 .. REAGENT or RESOURCE SOURCE IDENTIFIER Critical commercial assays poly-L-lysine MedChemExpress Cat# HY-126437K Optimal Cutting Temperature (OCT) compound Solarbio Cat# I7830 Protease inhibitor cocktail Proteintech Cat# PR20032 HypoxyprobeTM-1 Natural Pharmacia International Cat# HP3-100Kit P3 Primary Cell 4D-Nucleofector X Unit Reagent Kit L LONZA LONZA-V4XP-3024 IFN-γ ELISpot Kit Dayo Cat#2210005 DAPI Dihydrochloride Proteintech 28718-90-3 Deposited data snRNA-seq data (human PDAC tissues) This study National Omics Data Encyclopedia, OEP00006497 RNA-seq data (cell lines) This study National Omics Data Encyclopedia, OEZ00021631 Xenium 5K data (human PDAC tissues) This study National Omics Data Encyclopedia, OEZ00021630 snRNA-seq data (human PDAC tissues with neoadjuvant treatment) Hwang et al.11 GSE202051 scRNA-seq data (human PDAC tissues, #1) Steele et al. GSE155698 scRNA-seq data (human PDAC tissues, #2) Peng et al.12 CRA001160 scRNA-seq data (human PDAC tissues, #3) Lin et al. GSE154778 Experimental models: Cell lines MIA PaCa-2 American Type Culture Collection CRL-1420 CFPAC-1 American Type Culture Collection CRL-1918 SW1990 American Type Culture Collection CRL-2172 PANC-1 American Type Culture Collection CRL-1469 αTC1-6 American Type Culture Collection CRL-2934 THP-1 American Type Culture Collection TIB-202 HUVEC American Type Culture Collection PCS-100-013 HPDE6-C7 Anwei-sci Cell Center AW-CH0777 KPC-0116 FUSCC https://doi.org/10.1016/j. xcrm.2023.101234 Patient-derived CAFs FUSCC https://doi.org/10.1016/j. csbj.2024.04.021. .. Oligonucleotides siRNA targeting human PLOD2, si#1: GGAACACUAUGCUGAUCAAtt GeneAdv N/A siRNA targeting human PLOD2, si#2: GGUCCUUGGUICAAGGAGAAtt GeneAdv N/A siRNA targeting mouse PLOD2, si#2: CGAAGGACUUCCUGUUAAATT GeneAdv N/A sg-PLOD2-1: AATGTAGAAGCATCATGATG Tsingke Biotech N/A sg-TRIM21-3 TCATCTCAGAGCTAGATCGA Tsingke Biotech N/A (Continued on next page) ll OPEN ACCESS Article e2 Cancer Cell 44, 1–16.e1–e11, August 10, 2026

    Enzyme-linked Immunospot:

    Article Title: Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies GAPDH Proteintech Cat# 60004-1-Ig; RRID:AB_2107436 PLOD2 Abcam Cat# ab313765 Cytokeratin 19 Aifang Cat# AFRM0054 CD31 Abcam Cat# ab281583; RRID:AB_3096925 Fibronectin Proteintech Cat# 66042-1-Ig; RRID:AB_11182385 S100A2 Proteintech Cat# 15454-1-AP; RRID:AB_3669209 GATA6 Proteintech Cat# 55435-1-AP; RRID:AB_11182815 Paxillin Proteintech Cat# 10029-1-Ig; RRID:AB_513929 Integrin β1 Aifang Cat# AFRM0070 alpha smooth muscle Abcam Cat# ab7817; RRID:AB_262054 FAP Proteintech Cat# 11779-1-AP; RRID:AB_3669133 DUSP6 Proteintech Cat# 26071-1-AP; RRID:AB_3669521 ANGPTL4 Proteintech Cat# 18374-1-AP; RRID:AB_2878539 NDRG1 Proteintech Cat# 26902-1-AP; RRID:AB_2880676 CD45 Abcam Cat# ab281586; RRID:AB_3697165 MCTP2 Proteintech Cat# 17578-1-AP; RRID:AB_2143118 CD3 Abcam Cat# ab16669; RRID:AB_443425 CD68 Abcam Cat# ab283654; RRID:AB_2922954 SYN Proteintech Cat# 17785-1-AP; RRID:AB_2271365 IGF1R Proteintech Cat# 20254-1-AP; RRID:AB_10667455 PPP2R2C Proteintech Cat# 12747-1-AP; RRID:AB_2170099 hCD45 BioLegend Cat# 304008; RRID:AB_314396 mCD45 BioLegend Cat# 103112; RRID:AB_312977 HLA-G Proteintech Cat# 66447-1-Ig anti-Myc-Tag Cell Signaling Technology Cat# 2278; RRID: AB_490778 anti-FLAG Cell Signaling Technology Cat# 14793; RRID: AB_2572291 anti-HA Abcam Cat #ab9110, RRID: AB_307019 Biological samples Human pancreatic cancer tissues This study N/A Patient-derived xenografts This study N/A Chemicals, peptides, and recombinant proteins PROTAC-G3 This study N/A Activin A MedChemExpress Cat# HY-P70311 MG-132 MedChemExpress Cat# HY-13259 Latrunculin A Abcam Cat# ab144290 KP-457 MedChemExpress Cat# HY-110397 Cycloheximide MedChemExpress Cat# HY-12320 (S)-ACE-OH MedChemExpress Cat# HY169325 OVA Peptide MedChemExpress Cat# HY-P1489 Recombinant Streptococcus pyogenes CRISPR-Cas9 Protein (His Tag) SinoBiological Cat: 40572-A08B (Continued on next page) ll OPEN ACCESSArticle Cancer Cell 44, 1–16.e1–e11, August 10, 2026 e1 .. REAGENT or RESOURCE SOURCE IDENTIFIER Critical commercial assays poly-L-lysine MedChemExpress Cat# HY-126437K Optimal Cutting Temperature (OCT) compound Solarbio Cat# I7830 Protease inhibitor cocktail Proteintech Cat# PR20032 HypoxyprobeTM-1 Natural Pharmacia International Cat# HP3-100Kit P3 Primary Cell 4D-Nucleofector X Unit Reagent Kit L LONZA LONZA-V4XP-3024 IFN-γ ELISpot Kit Dayo Cat#2210005 DAPI Dihydrochloride Proteintech 28718-90-3 Deposited data snRNA-seq data (human PDAC tissues) This study National Omics Data Encyclopedia, OEP00006497 RNA-seq data (cell lines) This study National Omics Data Encyclopedia, OEZ00021631 Xenium 5K data (human PDAC tissues) This study National Omics Data Encyclopedia, OEZ00021630 snRNA-seq data (human PDAC tissues with neoadjuvant treatment) Hwang et al.11 GSE202051 scRNA-seq data (human PDAC tissues, #1) Steele et al. GSE155698 scRNA-seq data (human PDAC tissues, #2) Peng et al.12 CRA001160 scRNA-seq data (human PDAC tissues, #3) Lin et al. GSE154778 Experimental models: Cell lines MIA PaCa-2 American Type Culture Collection CRL-1420 CFPAC-1 American Type Culture Collection CRL-1918 SW1990 American Type Culture Collection CRL-2172 PANC-1 American Type Culture Collection CRL-1469 αTC1-6 American Type Culture Collection CRL-2934 THP-1 American Type Culture Collection TIB-202 HUVEC American Type Culture Collection PCS-100-013 HPDE6-C7 Anwei-sci Cell Center AW-CH0777 KPC-0116 FUSCC https://doi.org/10.1016/j. xcrm.2023.101234 Patient-derived CAFs FUSCC https://doi.org/10.1016/j. csbj.2024.04.021. .. Oligonucleotides siRNA targeting human PLOD2, si#1: GGAACACUAUGCUGAUCAAtt GeneAdv N/A siRNA targeting human PLOD2, si#2: GGUCCUUGGUICAAGGAGAAtt GeneAdv N/A siRNA targeting mouse PLOD2, si#2: CGAAGGACUUCCUGUUAAATT GeneAdv N/A sg-PLOD2-1: AATGTAGAAGCATCATGATG Tsingke Biotech N/A sg-TRIM21-3 TCATCTCAGAGCTAGATCGA Tsingke Biotech N/A (Continued on next page) ll OPEN ACCESS Article e2 Cancer Cell 44, 1–16.e1–e11, August 10, 2026

    RNA Sequencing:

    Article Title: Mapping cell type-resolved transcriptomic profiles to patient survival in pancreatic cancer.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies GAPDH Proteintech Cat# 60004-1-Ig; RRID:AB_2107436 PLOD2 Abcam Cat# ab313765 Cytokeratin 19 Aifang Cat# AFRM0054 CD31 Abcam Cat# ab281583; RRID:AB_3096925 Fibronectin Proteintech Cat# 66042-1-Ig; RRID:AB_11182385 S100A2 Proteintech Cat# 15454-1-AP; RRID:AB_3669209 GATA6 Proteintech Cat# 55435-1-AP; RRID:AB_11182815 Paxillin Proteintech Cat# 10029-1-Ig; RRID:AB_513929 Integrin β1 Aifang Cat# AFRM0070 alpha smooth muscle Abcam Cat# ab7817; RRID:AB_262054 FAP Proteintech Cat# 11779-1-AP; RRID:AB_3669133 DUSP6 Proteintech Cat# 26071-1-AP; RRID:AB_3669521 ANGPTL4 Proteintech Cat# 18374-1-AP; RRID:AB_2878539 NDRG1 Proteintech Cat# 26902-1-AP; RRID:AB_2880676 CD45 Abcam Cat# ab281586; RRID:AB_3697165 MCTP2 Proteintech Cat# 17578-1-AP; RRID:AB_2143118 CD3 Abcam Cat# ab16669; RRID:AB_443425 CD68 Abcam Cat# ab283654; RRID:AB_2922954 SYN Proteintech Cat# 17785-1-AP; RRID:AB_2271365 IGF1R Proteintech Cat# 20254-1-AP; RRID:AB_10667455 PPP2R2C Proteintech Cat# 12747-1-AP; RRID:AB_2170099 hCD45 BioLegend Cat# 304008; RRID:AB_314396 mCD45 BioLegend Cat# 103112; RRID:AB_312977 HLA-G Proteintech Cat# 66447-1-Ig anti-Myc-Tag Cell Signaling Technology Cat# 2278; RRID: AB_490778 anti-FLAG Cell Signaling Technology Cat# 14793; RRID: AB_2572291 anti-HA Abcam Cat #ab9110, RRID: AB_307019 Biological samples Human pancreatic cancer tissues This study N/A Patient-derived xenografts This study N/A Chemicals, peptides, and recombinant proteins PROTAC-G3 This study N/A Activin A MedChemExpress Cat# HY-P70311 MG-132 MedChemExpress Cat# HY-13259 Latrunculin A Abcam Cat# ab144290 KP-457 MedChemExpress Cat# HY-110397 Cycloheximide MedChemExpress Cat# HY-12320 (S)-ACE-OH MedChemExpress Cat# HY169325 OVA Peptide MedChemExpress Cat# HY-P1489 Recombinant Streptococcus pyogenes CRISPR-Cas9 Protein (His Tag) SinoBiological Cat: 40572-A08B (Continued on next page) ll OPEN ACCESSArticle Cancer Cell 44, 1–16.e1–e11, August 10, 2026 e1 .. REAGENT or RESOURCE SOURCE IDENTIFIER Critical commercial assays poly-L-lysine MedChemExpress Cat# HY-126437K Optimal Cutting Temperature (OCT) compound Solarbio Cat# I7830 Protease inhibitor cocktail Proteintech Cat# PR20032 HypoxyprobeTM-1 Natural Pharmacia International Cat# HP3-100Kit P3 Primary Cell 4D-Nucleofector X Unit Reagent Kit L LONZA LONZA-V4XP-3024 IFN-γ ELISpot Kit Dayo Cat#2210005 DAPI Dihydrochloride Proteintech 28718-90-3 Deposited data snRNA-seq data (human PDAC tissues) This study National Omics Data Encyclopedia, OEP00006497 RNA-seq data (cell lines) This study National Omics Data Encyclopedia, OEZ00021631 Xenium 5K data (human PDAC tissues) This study National Omics Data Encyclopedia, OEZ00021630 snRNA-seq data (human PDAC tissues with neoadjuvant treatment) Hwang et al.11 GSE202051 scRNA-seq data (human PDAC tissues, #1) Steele et al. GSE155698 scRNA-seq data (human PDAC tissues, #2) Peng et al.12 CRA001160 scRNA-seq data (human PDAC tissues, #3) Lin et al. GSE154778 Experimental models: Cell lines MIA PaCa-2 American Type Culture Collection CRL-1420 CFPAC-1 American Type Culture Collection CRL-1918 SW1990 American Type Culture Collection CRL-2172 PANC-1 American Type Culture Collection CRL-1469 αTC1-6 American Type Culture Collection CRL-2934 THP-1 American Type Culture Collection TIB-202 HUVEC American Type Culture Collection PCS-100-013 HPDE6-C7 Anwei-sci Cell Center AW-CH0777 KPC-0116 FUSCC https://doi.org/10.1016/j. xcrm.2023.101234 Patient-derived CAFs FUSCC https://doi.org/10.1016/j. csbj.2024.04.021. .. Oligonucleotides siRNA targeting human PLOD2, si#1: GGAACACUAUGCUGAUCAAtt GeneAdv N/A siRNA targeting human PLOD2, si#2: GGUCCUUGGUICAAGGAGAAtt GeneAdv N/A siRNA targeting mouse PLOD2, si#2: CGAAGGACUUCCUGUUAAATT GeneAdv N/A sg-PLOD2-1: AATGTAGAAGCATCATGATG Tsingke Biotech N/A sg-TRIM21-3 TCATCTCAGAGCTAGATCGA Tsingke Biotech N/A (Continued on next page) ll OPEN ACCESS Article e2 Cancer Cell 44, 1–16.e1–e11, August 10, 2026



    Similar Products

    86
    Biomax Inc human pdac tissue array
    (A) Representative IHC staining <t>of</t> <t>ITGB3</t> in <t>PDAC</t> tissue microarrays (TMA) showing varying expression levels in non-cancer and cancer tissue sections. (B). High magnification IHC images demonstrating the expression of ITGB3 on normal pancreas and cancer cells with stromal regions. (D-I) . Scatter plots depicting the correlation between ITGB3 and key tumor-associated markers such as HIF-1α (D) , GLUT-1 (E) , VEGFA (F) , Vimentin (G) , COL1A1 (H) , and PECAM1 (I) . Pearson correlation coefficients (R) and p -values indicate statistically significant positive correlation between ITGB3 and these markers. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. All quantitative data represent the mean ± SEM. ∗∗∗∗p < 0.0001.
    Human Pdac Tissue Array, supplied by Biomax Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdac+tissue+array/array+slides+tissue/bio_rxiv__64898__2026__01__15__699725-59-16-21
    Average 86 stars, based on 1 article reviews
    human pdac tissue array - by Bioz Stars, 2026-10
    86/100 stars
      Buy from Supplier

    90
    TissueArray.com LLC human pdac tissue array
    (A) Representative IHC staining <t>of</t> <t>ITGB3</t> in <t>PDAC</t> tissue microarrays (TMA) showing varying expression levels in non-cancer and cancer tissue sections. (B). High magnification IHC images demonstrating the expression of ITGB3 on normal pancreas and cancer cells with stromal regions. (D-I) . Scatter plots depicting the correlation between ITGB3 and key tumor-associated markers such as HIF-1α (D) , GLUT-1 (E) , VEGFA (F) , Vimentin (G) , COL1A1 (H) , and PECAM1 (I) . Pearson correlation coefficients (R) and p -values indicate statistically significant positive correlation between ITGB3 and these markers. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. All quantitative data represent the mean ± SEM. ∗∗∗∗p < 0.0001.
    Human Pdac Tissue Array, supplied by TissueArray.com LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdac+tissue+array/human+pancreatic+cancer+tissue+array/pm39048609-54-1-9
    Average 90 stars, based on 1 article reviews
    human pdac tissue array - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    TissueArray.com LLC the human pdac tissue array
    STING expression in <t>human</t> <t>PDAC</t> stroma and CAFs. ( a ) Groups categorized by positive, weakly positive, and negative STING expression in PDAC stroma. Representative IHC analysis of STING using a human PDAC tissue array (scale bar, 100 μm). ( b ) Percentages of the indicated groups in 40 PDAC samples. ( c ) Co-immunofluorescence staining for α-SMA (red) and STING (green) in STING positive or weakly positive or negative in stroma. ( d ) 5-AZA (0.1 nM) was administered to CAF1 and CAF2 derived from murine PDACs and incubated for 24 h.
    The Human Pdac Tissue Array, supplied by TissueArray.com LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdac+tissue+array/human+pancreatic+cancer+tissue+array/pmc11269671-39-1-9
    Average 90 stars, based on 1 article reviews
    the human pdac tissue array - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    U.S Biomax Inc human pdac tissue array
    <t>a,</t> <t>Immunohistochemistry</t> staining of LPAR4 in a <t>PDAC</t> tissue array consisted of 15 PDAC samples and 4 samples of normal pancreas. Scale bar is 50 μM. Representative images showing normal pancreas (n=4 biological samples), low-LPAR4 PDAC (n=9 biological samples), and high-LPAR4 PDAC (n=6 biological samples). Bar graph shows the relative percentage of LPAR4-low and LPAR4-high patients in the PDAC tissue array. b, Quantitative RT-PCR confirming the manipulation of LPAR4 expression in 2 pancreatic cancer cell lines (Colo-357, MIA PaCa-2) and 2 patient-derived cancer cells (79E, 34E). Data were shown as mean ± s.d. (n=4 independent experiments for Colo-357 and 79E cells with LPAR4 stable knockdown, n=3 for Colo-357, 79E, and MiaPaCa2 cells with LPAR4 ectopic expression, n=3 for 34E cells with LPAR4 stable knockdown, and n=4 for 34E with LPAR4 ectopic expression). c, Non-invasive Bioluminescence images showing tumors formed at day 10 for Colo-357+sh-CTRL+luciferase or Colo-357+sh-R4.1+luciferase of various number implanted in the pancreas of nu/nu mice. Right panel showing the luminescence intensity in a blue-to-red spectrum. d, f, Trypan blue exclusion assay showing the relative number of viable cells with or without LPAR4 expression manipulation grown in 10% serum and 2D at day 4 and day 7. e, Tumor growth rates for 1 million Colo-357 cells with or without LPAR4 expression manipulation in a subcutaneous tumor model. Data were presented as mean ± s.d. for n=8 independent samples for each group. g, Quantitative RT-PCR confirming the knockdown of LPAR1 in Colo-357 cells. h, Effects of LPAR1 knockdown using siRNA on 2D or 3D (methylcellulose sphere forming) cell growth. Data were presented as mean ± s.d. for n=3 independent experiments (d,f,g, and h). Statistical analyses were performed using two tailed unpaired one sample t-test (b,g, and h) and one-way ANOVA (d-f). Source numerical data are available in source data.
    Human Pdac Tissue Array, supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdac+tissue+array/human+pancreatic+cancer+tissue+arrays/pmc10280815-636-7-11
    Average 90 stars, based on 1 article reviews
    human pdac tissue array - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    Pantomics Inc human pancreas cancer tissue array including 20 pdacs
    <t>a,</t> <t>Immunohistochemistry</t> staining of LPAR4 in a <t>PDAC</t> tissue array consisted of 15 PDAC samples and 4 samples of normal pancreas. Scale bar is 50 μM. Representative images showing normal pancreas (n=4 biological samples), low-LPAR4 PDAC (n=9 biological samples), and high-LPAR4 PDAC (n=6 biological samples). Bar graph shows the relative percentage of LPAR4-low and LPAR4-high patients in the PDAC tissue array. b, Quantitative RT-PCR confirming the manipulation of LPAR4 expression in 2 pancreatic cancer cell lines (Colo-357, MIA PaCa-2) and 2 patient-derived cancer cells (79E, 34E). Data were shown as mean ± s.d. (n=4 independent experiments for Colo-357 and 79E cells with LPAR4 stable knockdown, n=3 for Colo-357, 79E, and MiaPaCa2 cells with LPAR4 ectopic expression, n=3 for 34E cells with LPAR4 stable knockdown, and n=4 for 34E with LPAR4 ectopic expression). c, Non-invasive Bioluminescence images showing tumors formed at day 10 for Colo-357+sh-CTRL+luciferase or Colo-357+sh-R4.1+luciferase of various number implanted in the pancreas of nu/nu mice. Right panel showing the luminescence intensity in a blue-to-red spectrum. d, f, Trypan blue exclusion assay showing the relative number of viable cells with or without LPAR4 expression manipulation grown in 10% serum and 2D at day 4 and day 7. e, Tumor growth rates for 1 million Colo-357 cells with or without LPAR4 expression manipulation in a subcutaneous tumor model. Data were presented as mean ± s.d. for n=8 independent samples for each group. g, Quantitative RT-PCR confirming the knockdown of LPAR1 in Colo-357 cells. h, Effects of LPAR1 knockdown using siRNA on 2D or 3D (methylcellulose sphere forming) cell growth. Data were presented as mean ± s.d. for n=3 independent experiments (d,f,g, and h). Statistical analyses were performed using two tailed unpaired one sample t-test (b,g, and h) and one-way ANOVA (d-f). Source numerical data are available in source data.
    Human Pancreas Cancer Tissue Array Including 20 Pdacs, supplied by Pantomics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdac+tissue+array/pancreatic+cancer+tissue+array/pmc09763154-101-8-15
    Average 90 stars, based on 1 article reviews
    human pancreas cancer tissue array including 20 pdacs - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    90
    BioChain Institute human pdac tissue array
    <t>a,</t> <t>Immunohistochemistry</t> staining of LPAR4 in a <t>PDAC</t> tissue array consisted of 15 PDAC samples and 4 samples of normal pancreas. Scale bar is 50 μM. Representative images showing normal pancreas (n=4 biological samples), low-LPAR4 PDAC (n=9 biological samples), and high-LPAR4 PDAC (n=6 biological samples). Bar graph shows the relative percentage of LPAR4-low and LPAR4-high patients in the PDAC tissue array. b, Quantitative RT-PCR confirming the manipulation of LPAR4 expression in 2 pancreatic cancer cell lines (Colo-357, MIA PaCa-2) and 2 patient-derived cancer cells (79E, 34E). Data were shown as mean ± s.d. (n=4 independent experiments for Colo-357 and 79E cells with LPAR4 stable knockdown, n=3 for Colo-357, 79E, and MiaPaCa2 cells with LPAR4 ectopic expression, n=3 for 34E cells with LPAR4 stable knockdown, and n=4 for 34E with LPAR4 ectopic expression). c, Non-invasive Bioluminescence images showing tumors formed at day 10 for Colo-357+sh-CTRL+luciferase or Colo-357+sh-R4.1+luciferase of various number implanted in the pancreas of nu/nu mice. Right panel showing the luminescence intensity in a blue-to-red spectrum. d, f, Trypan blue exclusion assay showing the relative number of viable cells with or without LPAR4 expression manipulation grown in 10% serum and 2D at day 4 and day 7. e, Tumor growth rates for 1 million Colo-357 cells with or without LPAR4 expression manipulation in a subcutaneous tumor model. Data were presented as mean ± s.d. for n=8 independent samples for each group. g, Quantitative RT-PCR confirming the knockdown of LPAR1 in Colo-357 cells. h, Effects of LPAR1 knockdown using siRNA on 2D or 3D (methylcellulose sphere forming) cell growth. Data were presented as mean ± s.d. for n=3 independent experiments (d,f,g, and h). Statistical analyses were performed using two tailed unpaired one sample t-test (b,g, and h) and one-way ANOVA (d-f). Source numerical data are available in source data.
    Human Pdac Tissue Array, supplied by BioChain Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+pdac+tissue+array/Monkey+Tissue+Array+-+22+types+of+cyno+monkey+normal+tissues+covering+all+major+organs/pmc07766822-273-13-17
    Average 90 stars, based on 1 article reviews
    human pdac tissue array - by Bioz Stars, 2026-10
    90/100 stars
      Buy from Supplier

    Image Search Results


    (A) Representative IHC staining of ITGB3 in PDAC tissue microarrays (TMA) showing varying expression levels in non-cancer and cancer tissue sections. (B). High magnification IHC images demonstrating the expression of ITGB3 on normal pancreas and cancer cells with stromal regions. (D-I) . Scatter plots depicting the correlation between ITGB3 and key tumor-associated markers such as HIF-1α (D) , GLUT-1 (E) , VEGFA (F) , Vimentin (G) , COL1A1 (H) , and PECAM1 (I) . Pearson correlation coefficients (R) and p -values indicate statistically significant positive correlation between ITGB3 and these markers. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. All quantitative data represent the mean ± SEM. ∗∗∗∗p < 0.0001.

    Journal: bioRxiv

    Article Title: ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment

    doi: 10.64898/2026.01.15.699725

    Figure Lengend Snippet: (A) Representative IHC staining of ITGB3 in PDAC tissue microarrays (TMA) showing varying expression levels in non-cancer and cancer tissue sections. (B). High magnification IHC images demonstrating the expression of ITGB3 on normal pancreas and cancer cells with stromal regions. (D-I) . Scatter plots depicting the correlation between ITGB3 and key tumor-associated markers such as HIF-1α (D) , GLUT-1 (E) , VEGFA (F) , Vimentin (G) , COL1A1 (H) , and PECAM1 (I) . Pearson correlation coefficients (R) and p -values indicate statistically significant positive correlation between ITGB3 and these markers. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. All quantitative data represent the mean ± SEM. ∗∗∗∗p < 0.0001.

    Article Snippet: To evaluate the role of ITGB3 in PDAC, we analyzed its expression using IHC in a human PDAC tissue array (PA483-L97, Biomax) that contains 40 cancer and eight non-cancer tissues ( Supplementary Table 1 ).

    Techniques: Immunohistochemistry, Expressing, Two Tailed Test

    STING expression in human PDAC stroma and CAFs. ( a ) Groups categorized by positive, weakly positive, and negative STING expression in PDAC stroma. Representative IHC analysis of STING using a human PDAC tissue array (scale bar, 100 μm). ( b ) Percentages of the indicated groups in 40 PDAC samples. ( c ) Co-immunofluorescence staining for α-SMA (red) and STING (green) in STING positive or weakly positive or negative in stroma. ( d ) 5-AZA (0.1 nM) was administered to CAF1 and CAF2 derived from murine PDACs and incubated for 24 h.

    Journal: Scientific Reports

    Article Title: Activation of STING in pancreatic cancer-associated fibroblasts exerts an antitumor effect by enhancing tumor immunity

    doi: 10.1038/s41598-024-68061-y

    Figure Lengend Snippet: STING expression in human PDAC stroma and CAFs. ( a ) Groups categorized by positive, weakly positive, and negative STING expression in PDAC stroma. Representative IHC analysis of STING using a human PDAC tissue array (scale bar, 100 μm). ( b ) Percentages of the indicated groups in 40 PDAC samples. ( c ) Co-immunofluorescence staining for α-SMA (red) and STING (green) in STING positive or weakly positive or negative in stroma. ( d ) 5-AZA (0.1 nM) was administered to CAF1 and CAF2 derived from murine PDACs and incubated for 24 h.

    Article Snippet: The human PDAC tissue array was purchased commercially from TissueArray.com (No.PA482a).

    Techniques: Expressing, Immunofluorescence, Staining, Derivative Assay, Incubation

    a, Immunohistochemistry staining of LPAR4 in a PDAC tissue array consisted of 15 PDAC samples and 4 samples of normal pancreas. Scale bar is 50 μM. Representative images showing normal pancreas (n=4 biological samples), low-LPAR4 PDAC (n=9 biological samples), and high-LPAR4 PDAC (n=6 biological samples). Bar graph shows the relative percentage of LPAR4-low and LPAR4-high patients in the PDAC tissue array. b, Quantitative RT-PCR confirming the manipulation of LPAR4 expression in 2 pancreatic cancer cell lines (Colo-357, MIA PaCa-2) and 2 patient-derived cancer cells (79E, 34E). Data were shown as mean ± s.d. (n=4 independent experiments for Colo-357 and 79E cells with LPAR4 stable knockdown, n=3 for Colo-357, 79E, and MiaPaCa2 cells with LPAR4 ectopic expression, n=3 for 34E cells with LPAR4 stable knockdown, and n=4 for 34E with LPAR4 ectopic expression). c, Non-invasive Bioluminescence images showing tumors formed at day 10 for Colo-357+sh-CTRL+luciferase or Colo-357+sh-R4.1+luciferase of various number implanted in the pancreas of nu/nu mice. Right panel showing the luminescence intensity in a blue-to-red spectrum. d, f, Trypan blue exclusion assay showing the relative number of viable cells with or without LPAR4 expression manipulation grown in 10% serum and 2D at day 4 and day 7. e, Tumor growth rates for 1 million Colo-357 cells with or without LPAR4 expression manipulation in a subcutaneous tumor model. Data were presented as mean ± s.d. for n=8 independent samples for each group. g, Quantitative RT-PCR confirming the knockdown of LPAR1 in Colo-357 cells. h, Effects of LPAR1 knockdown using siRNA on 2D or 3D (methylcellulose sphere forming) cell growth. Data were presented as mean ± s.d. for n=3 independent experiments (d,f,g, and h). Statistical analyses were performed using two tailed unpaired one sample t-test (b,g, and h) and one-way ANOVA (d-f). Source numerical data are available in source data.

    Journal: Nature cell biology

    Article Title: Pancreatic cancer cells upregulate LPAR4 in response to isolation stress to promote an ECM-enriched niche and support tumor initiation

    doi: 10.1038/s41556-022-01055-y

    Figure Lengend Snippet: a, Immunohistochemistry staining of LPAR4 in a PDAC tissue array consisted of 15 PDAC samples and 4 samples of normal pancreas. Scale bar is 50 μM. Representative images showing normal pancreas (n=4 biological samples), low-LPAR4 PDAC (n=9 biological samples), and high-LPAR4 PDAC (n=6 biological samples). Bar graph shows the relative percentage of LPAR4-low and LPAR4-high patients in the PDAC tissue array. b, Quantitative RT-PCR confirming the manipulation of LPAR4 expression in 2 pancreatic cancer cell lines (Colo-357, MIA PaCa-2) and 2 patient-derived cancer cells (79E, 34E). Data were shown as mean ± s.d. (n=4 independent experiments for Colo-357 and 79E cells with LPAR4 stable knockdown, n=3 for Colo-357, 79E, and MiaPaCa2 cells with LPAR4 ectopic expression, n=3 for 34E cells with LPAR4 stable knockdown, and n=4 for 34E with LPAR4 ectopic expression). c, Non-invasive Bioluminescence images showing tumors formed at day 10 for Colo-357+sh-CTRL+luciferase or Colo-357+sh-R4.1+luciferase of various number implanted in the pancreas of nu/nu mice. Right panel showing the luminescence intensity in a blue-to-red spectrum. d, f, Trypan blue exclusion assay showing the relative number of viable cells with or without LPAR4 expression manipulation grown in 10% serum and 2D at day 4 and day 7. e, Tumor growth rates for 1 million Colo-357 cells with or without LPAR4 expression manipulation in a subcutaneous tumor model. Data were presented as mean ± s.d. for n=8 independent samples for each group. g, Quantitative RT-PCR confirming the knockdown of LPAR1 in Colo-357 cells. h, Effects of LPAR1 knockdown using siRNA on 2D or 3D (methylcellulose sphere forming) cell growth. Data were presented as mean ± s.d. for n=3 independent experiments (d,f,g, and h). Statistical analyses were performed using two tailed unpaired one sample t-test (b,g, and h) and one-way ANOVA (d-f). Source numerical data are available in source data.

    Article Snippet: Immunohistochemistry staining of LPAR4 or FN1 in human PDAC tissue array (US Biomax PA484a) or formalin-fixed, paraffin-embedded xenograft tumors were performed using the LPAR4 antibody (Thermo Fisher, #PA5–49727) or FN1 antibody (CST, #26836, E5H6X) following the manufacturer’s protocol.

    Techniques: Immunohistochemistry, Staining, Quantitative RT-PCR, Expressing, Derivative Assay, Luciferase, Trypan Blue Exclusion Assay, Two Tailed Test